Scope, Claims, and US Patent Landscape for 11,369,597
United States Drug Patent 11,369,597 is directed to a specific post-gemcitabine treatment regimen for metastatic pancreatic adenocarcinoma, pairing irinotecan sucrose octasulfate salt liposome injection (an irinotecan prodrug formulation in liposomes) with leucovorin and 5-fluorouracil (5-FU), dosed on a once-every-two-weeks schedule and tied to pharmacokinetic (PK) performance metrics for SN-38 after administration. The core claim structure combines (1) patient population and line of therapy, (2) exact drug forms and dose levels, (3) administration timing, and (4) exposure/PK constraints for the irinotecan liposome product.
Because the prompt provides the claims but does not provide the patent’s specification, prosecution history, priority claims, or bibliographic identifiers beyond the US number, the landscape below is limited to claim-scope inference from the text of the claims provided and industry-standard competitive vectors that typically determine freedom-to-operate around irinotecan-based liposome regimens in pancreas cancer. No other patent documents are cited because no additional patent identifiers or citation lists were supplied.
What does claim 1 cover (the dominant scope)?
Claim 1: method-of-treatment combination with embedded product and PK constraints
Claim 1 defines a method of treating:
- Condition / population: “metastatic adenocarcinoma of the pancreas” in a human patient
- Prior therapy: patient “previously been treated with … gemcitabine”
- Treatment frequency: “once every two weeks”
- Therapy components (all must be present):
- Irinotecan sucrose octasulfate salt liposome injection
- Dosage equivalence: “amount providing the equivalent of 70 mg/m2 of irinotecan free base”
- Form requirement: “irinotecan … encapsulated in liposomes”
- PK limitation after administration: mean total SN-38 terminal elimination half-life
- “67.8 ± 44.5 hours”
- Leucovorin
- “200 mg/m2 of the (l) form” or
- “400 mg/m2 of the (l+d) racemic form”
- 5-Fluorouracil (5-FU)
What is the legal “center of gravity”
Claim 1 is not a generic “irinotecan + leucovorin + 5-FU” regimen. It is a hybrid of:
- Indication and line-of-therapy anchor (metastatic pancreatic adenocarcinoma; post-gemcitabine)
- Specific irinotecan formulation (sucrose octasulfate salt, liposomal encapsulation, dose expressed as irinotecan free base equivalent)
- Specific SN-38 PK behavioral limitation (half-life mean and spread)
- Fixed leucovorin stereoisomer logic (l-only versus l+d) and fixed 5-FU dose
- Fixed cadence (every 2 weeks)
For infringement, an accused method must satisfy all claim elements, including the formulation and the SN-38 terminal half-life limitation as written (typically requiring evidence tied to in vivo measurements under the asserted administration context).
How narrow are dependent claims 2–13?
Claim 2: administration schedule is locked
Claim 2 adds timed infusion windows:
- Irinotecan liposome injection: IV over 90 minutes
- Leucovorin: IV over 30 minutes
- 5-FU: IV over 46 hours
This materially narrows practice patterns: even if dose levels match, differing infusion duration can avoid literal coverage if the claim is strictly construed.
Claim 3: progression on gemcitabine-based therapy
Claim 3 tightens the patient anchor to:
- metastatic pancreatic adenocarcinoma “progressed on gemcitabine-based therapy” prior to the irinotecan liposome regimen.
This excludes patients who merely received gemcitabine without progression (depending on claim construction).
Claim 4–6: PK exposure constraints introduce a second layer of limitation
Claim 4 adds a proportionality constraint on exposure:
- “following administration … SN-38 AUC0-∞ increases less than proportionally with the dose”
Claim 5 locks the exposure magnitude:
- mean total SN-38 AUC0-∞ = 620 ± 329 h·ng/mL
Claim 6 locks maximum concentration:
- mean total SN-38 Cmax = 5.4 ± 3.4 ng/mL
These claims create a PK phenotype requirement that competitors often cannot guarantee without matching the exact formulation, dosing, schedule, and subject population enough to land within the claimed statistical ranges.
Claim 7: leucovorin form narrows to the racemate
Claim 7 selects one branch of claim 1:
- leucovorin provided by “400 mg/m2 of the (l+d) form”
This is narrower than claim 1, but it still covers a large portion of dosing choices where the racemate is used.
Claim 8: anti-emetic premedication
Claim 8 adds:
- “further comprising premediating … with an anti-emetic”
This broadens practical coverage for actual clinical protocols that include prophylaxis. It can also reduce design-around by omission if the claim is interpreted to require anti-emetic administration only when included, which is typical for method claims in chemotherapy regimens.
Claim 9–13: liposome composition and physical properties
Claims 9–13 substantially narrow the irinotecan liposome “product definition.”
Claim 9 (lipid identity):
- irinotecan sucrose octasulfate liposome injection contains
“N-(methoxy-poly(ethyleneglycol) (M.W. 2000)-oxycarbonyl)-distearoylphosphatidylethanolamine”
(PEG2000-DSPE-COOH or an equivalent named component).
Claim 10 (molar ratio):
- phosphatidylcholine : cholesterol : PEG2000-DSPE-COOH = 3 : 2 : 0.015
Claim 11 (size range):
- liposomes “average size from about 80 to about 140 nm”
measured by QELS using Gaussian model (volume-averaged mean).
Claim 12 (preferred size):
- average size about 110 nm by the same method.
Claim 13 (filtering):
- liposomes filtered through a 0.2 micron filter.
Taken together, these dependent claims define both chemical composition and manufacturing/characterization conditions. A competitor using a different lipid ratio, different PEG-lipid identity, different particle size distribution, or different filtration steps risks avoiding these dependent claims even if the method-of-treatment elements remain similar.
What is the practical infringement “map” for competitors?
To infringe claim 1 (baseline), an accused regimen must match all:
- metastatic pancreatic adenocarcinoma
- human patient
- prior gemcitabine treatment
- once-every-two-weeks dosing
- irinotecan sucrose octasulfate liposomal formulation providing irinotecan free base equivalent 70 mg/m2
- leucovorin at 200 mg/m2 (l) or 400 mg/m2 (l+d)
- 5-FU 2,400 mg/m2
- mean total SN-38 terminal elimination half-life 67.8 ± 44.5 hours
To infringe claim 2, 4–6, and 9–13, it must also match:
- infusion durations (90 min / 30 min / 46 hours)
- SN-38 exposure phenotype (less-than-proportional AUC with dose; AUC0-∞ and Cmax statistical targets)
- liposome lipid components and molar ratios
- liposome particle size range and/or about 110 nm
- 0.2 micron filtration
Most sensitive design-around points
From the claim text, the most “surgical” avoidance levers are:
- changing liposomal composition (claims 9–10)
- changing particle size distribution / measurement approach (claims 11–12)
- changing manufacturing filtration step (claim 13)
- changing infusion time schedule (claim 2)
- changing PK performance to fall outside claimed SN-38 mean ranges (claims 4–6)
- using a leucovorin format outside the claimed (l) or (l+d) choices at the specified dose logic
How does this claim set position the patent in the pancreatic cancer regimen landscape?
Claim strategy: a regimen patent with a product-and-PK moat
This patent does not read like a broad “drug class” patent. The combination of:
- irinotecan sucrose octasulfate liposome
- fixed dose levels
- fixed infusion durations
- and hard SN-38 PK thresholds
is typical of claims that aim to capture a specific development candidate and clinical protocol, not an entire therapeutic concept.
Commercially relevant read across
In practice, the competitive space for metastatic pancreatic adenocarcinoma after gemcitabine is concentrated on:
- regimens built around 5-FU / leucovorin / irinotecan backbones, and
- irinotecan delivered in special formulations to shift PK and tolerability.
This patent’s novelty sits in the specific liposomal irinotecan sucrose octasulfate delivery plus measured SN-38 PK.
Patent landscape: where this US patent likely sits relative to adjacent IP types
No citations or related-family data were supplied, so the analysis below is structured by IP adjacency categories that typically govern freedom-to-operate around a regimen like this.
1) Product formulation IP (liposome composition and process)
This patent includes dependent claims on:
- specific PEG-lipid
- molar ratio of lipids
- particle size range
- filtration through 0.2 micron
These elements suggest the family likely intersects with formulation IP owned by the irinotecan liposome developer. The enforceable scope would extend to methods using that formulation, even when the therapeutic regimen is similar.
2) Regimen IP (dosing cadence and infusion schedule)
Claims 1–3 and 2 define:
- once every two weeks
- infusion durations
Regimen IP is often harder to design around clinically because it is tied to the protocol used in trials and labels, but it can be avoided if competitors adopt materially different scheduling.
3) Clinical endpoint-derived PK IP (SN-38 exposure phenotype)
Claims 1 and 4–6 embed:
- SN-38 terminal half-life
- SN-38 AUC0-∞
- SN-38 Cmax
- dose-exposure nonlinearity
This type of limitation typically requires that an accused product run close to the same PK profile in representative patients. It is a strong moat against substitutes that alter:
- formulation structure
- dosing unit equivalence
- administration timing
- or patient selection criteria
4) Indication / line-of-therapy IP (post-gemcitabine)
Claims 1 and 3 target gemcitabine-treated and specifically progressed-on gemcitabine-based therapy.
This can reduce infringement risk against use in lines outside the claim scope, but it also means market threats are strongest where uptake is in the post-gemcitabine window.
What the claim text implies about enforceability and litigation posture
1) Method claims with product/PK limitations can be assertion-heavy
If the asserted claims require matching PK statistics, infringement analysis will likely focus on:
- PK reporting from clinical studies of the accused regimen
- comparability of SN-38 measurements
- whether the accused schedule and dosing unit conversion align with the claim’s equivalence language
2) Dependent claims increase specificity, which can narrow the path to trial
A claimant can choose:
- a broader independent claim (claim 1) based on its formulation and SN-38 half-life
- then layer dependent claims for stronger “match” evidence when formulation metrics are available
3) Design-around can focus on formulation metrics
Because claims 9–13 include lipid ratio and physical size and filtration, competitors can attempt substitution with:
- different lipid composition ratios
- different PEG-lipid variant
- different particle size target
- different filtration/sterilization process
Key Takeaways
- Claim 1 is a post-gemcitabine treatment method for metastatic pancreatic adenocarcinoma using a specific liposomal irinotecan sucrose octasulfate formulation dosed as 70 mg/m2 irinotecan free base equivalent, combined with leucovorin (l form 200 mg/m2 or l+d 400 mg/m2) and 5-FU 2,400 mg/m2, dosed once every two weeks, and tied to an SN-38 terminal elimination half-life of 67.8 ± 44.5 hours.
- Claim 2 adds a tightly defined infusion schedule: irinotecan 90 min, leucovorin 30 min, 5-FU 46 hours.
- Claims 4–6 add a second moat based on SN-38 exposure phenotype (less-than-proportional AUC with dose; AUC0-∞ 620 ± 329 h·ng/mL; Cmax 5.4 ± 3.4 ng/mL).
- Claims 9–13 define the irinotecan liposome at the composition and characterization level (PEG2000-DSPE-COOH identity, 3:2:0.015 lipid molar ratio, 80–140 nm or about 110 nm size by QELS Gaussian volume average, and 0.2 micron filtering).
- The enforceable scope is best described as a regimen patent anchored to a specific liposomal product and PK-defined SN-38 behavior, not a broad irinotecan-5FU combination.
FAQs
1) Does 11,369,597 cover any irinotecan + leucovorin + 5-FU regimen in pancreatic cancer?
No. It is limited to metastatic pancreatic adenocarcinoma after prior gemcitabine and requires the specific irinotecan sucrose octasulfate salt liposome injection at 70 mg/m2 irinotecan free base equivalent plus defined leucovorin and 5-FU dosing, with an SN-38 terminal half-life limitation.
2) Is the once-every-two-weeks dosing cadence essential?
Yes. Claim 1 requires administering the antineoplastic therapy once every two weeks, making scheduling an important scope element.
3) Which claims incorporate measurable PK targets for SN-38?
Claim 1 includes the SN-38 terminal elimination half-life. Claims 4–6 include AUC0-∞ nonlinearity, AUC0-∞ magnitude, and Cmax targets.
4) Can a competitor avoid dependent claims 9–13 by changing liposome composition?
The claims explicitly require a specified PEG-lipid presence and a specific lipid molar ratio and particle size parameters. Substituting those attributes can be a direct design-around strategy for those dependent claims.
5) Does claim 2 only change administration timing or does it affect core coverage?
It narrows coverage by requiring specific infusion durations for each component, layering additional constraints on top of claim 1.
References
[1] US Patent 11,369,597 (claims provided in prompt).
